Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
During the month of October, Henlius signed two agreements for its biosimilar products and presented results of HLX03 (biosimilar, adalimumab) whereas Samsung Bioepis and Biogen announced EMA filing acceptance of SB11 (biosimilar, ranibizumab)
Our team at PharmaShots…
